Alpine Associates Management’s Tourmaline Bio TRML Stock Holding History

Alpine Associates Management’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-196,177	Closed	-$9.38M	–	97
2025 Q3	$9.38M	Buy	+196,177	New	+$5.44M	0.57%	37

Alpine Associates Management's TRML Position: Q4 2025 in Review

Alpine Associates Management sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 196,177 shares — an estimated $9.38M sold.

Alpine Associates Management first reported a position in TRML in Q3 2025 and held it in 1 quarter. The position peaked at $9.38M in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

Alpine Associates Management reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
Alpine Associates Management sold 196,177 Tourmaline Bio shares in Q4 2025, an estimated $9.38M.
Alpine Associates Management first reported a position in Tourmaline Bio in Q3 2025 and held it in 1 quarter.
Alpine Associates Management's Tourmaline Bio position peaked at $9.38M in Q3 2025.
0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on Alpine Associates Management's 13F filing for Q4 2025, filed 5 Feb 2026.